Across TCGA pan-cancer cohorts, FEM1AP3 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of FEM1AP3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where FEM1AP3 RNA is repressed in tumor relative to normal tissue. In most cancer types FEM1AP3 is over-expressed in tumor, although a few such as KIRP and KIRC show the opposite, repressed pattern.

KIRP, KIRC, and THCA are the cancer types where FEM1AP3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in FEM1AP3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRP	All	All	−0.021	<.001	9	view →
KIRC	All	All	−0.026	<.001	7	view →
THCA	Female	II,III,IV	+0.044	.020	2	view →
ESCA	All	All	−0.067	.031	1	view →
THCA	Male	All	−0.014	.044	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 4 lineages.

Exploration

Same gene, other analysis: FEM1AP3 RNA expression & survival · all FEM1AP3 data types